WallStSmart

Bluejay Diagnostics Inc (BJDX)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MDT leads profitability with a 13.9% profit margin vs 0.0%. MDT earns a higher WallStSmart Score of 68/100 (B-).

BJDX

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -7.47

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BJDX.

MDTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$94.43

Current Price

$90.96

$3.47 discount

UndervaluedFair: $94.43Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BJDX2 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$116.35B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

Areas to Watch

BJDX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$928,4503/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BJDX

The strongest argument for BJDX centers on Price/Book, Debt/Equity.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bear Case : BJDX

The primary concerns for BJDX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

BJDX carries more volatility with a beta of 0.91 — expect wider price swings.

MDT is growing revenue faster at 13.7% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (68/100 vs 26/100) and 13.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bluejay Diagnostics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Bluejay Diagnostics Inc. is an innovative medical technology company focused on revolutionizing patient care through its cutting-edge diagnostic solutions, with a strong emphasis on early disease detection. Utilizing a proprietary platform that combines advanced artificial intelligence with point-of-care testing, Bluejay enhances diagnostic accuracy and accelerates result delivery, thereby equipping healthcare providers with critical insights in real-time. The company is strategically poised to confront notable healthcare challenges and fulfill the growing demand for reliable and advanced diagnostic tools, leveraging its robust commitment to research and development in a rapidly evolving medical landscape.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?